The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts

BACKGROUND: Oral migalastat has recently been approved for the treatment of Anderson-Fabry disease (FD) in patients aged ≥16 years with amenable mutations on the basis of two phase III trials, FACETS and ATTRACT. However, with the introduction of migalastat into clinical practice, it is important to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimenti, Cristina, Nencini, Patrizia, Pieruzzi, Federico, Feriozzi, Sandro, Mignani, Renzo, Pieroni, Maurizio, Pisani, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140546/
https://www.ncbi.nlm.nih.gov/pubmed/32264911
http://dx.doi.org/10.1186/s13023-020-1318-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140546/
https://www.ncbi.nlm.nih.gov/pubmed/32264911
http://dx.doi.org/10.1186/s13023-020-1318-8

Ejemplares similares